Research  >  About SRI  >  Scientist Profiles
Share:  
|
PAGE
MENU

Scientist profiles G-L

SRI Profiles

Nathan Herrmann, MD, FRCP(C)

Associate scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room FG 19
Toronto, ON
M4N 3M5

Phone: 416-480-5070
Fax: 416-480-6022

Administrative Assistant: Kathy Ostaff
Phone: 416-480-5013
Email: kathy.ostaff@sunnybrook.ca 

Education:

  • MD, 1983, University of Toronto, Canada
  • FRCP(C), 1988, psychiatry, U of T, Canada

Appointments and Affiliations:

  • Associate scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute 
  • Richard Lewar Chair in Geriatric Psychiatry, Sunnybrook Health Sciences Centre and U of T
  • Head, division of geriatric psychiatry, Sunnybrook Health Sciences Centre
  • Head, division of geriatric psychiatry, department of psychiatry, U of T (1995–2005)
  • Professor, department of psychiatry, faculty of medicine, U of T

Research Foci:

  • Clinical neuropharmacology
  • Geriatric psychiatry

Research Summary:

Dr. Herrmann's major contributions to neuroscience research are in the areas of the clinical pharmacology of dementia (treatment of behavioural disturbances and cognition), post-stroke depression and the pharmacotherapy of late-life affective disorders. He has published numerous studies on the pharmacotherapy of behavioural disturbances in dementia that involve the use of novel agents, which attempt to determine the underlying neurobiology of these disorders. He has also participated in studies of post-stroke depression examining its neuroimaging and biological correlates. In addition, he has published studies, reviews and guidelines on the management of depression and bipolar illness in late-life, and has participated in psychopharmacology projects on drug-drug interactions and adverse events.

Selected Publications:

See current publications list at PubMed.

  1. Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in moderate to severe Alzheimer’s disease patients. J Am Med Dir Assoc. 2016 Feb;17:142–7.
  2. Herrmann N, Harimoto T, Balshaw R, Lanctôt KL. The Canadian outcomes study of dementia (COSID) investigators: Risk factors for progression of Alzheimer’s disease in a Canadian population: The Canadian outcomes study in dementia (COSID). Can J Psychiatry. 2015 Apr;60(4):189–199.
  3. Herrmann N, Hogan D, Lanctôt KL. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5.
  4. Herrmann N, Gauthier S, Boneva N, Lemming OM. A randomized, double-blind placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr. 2013 Jun;25(6):919–27.

    Related News and Stories:

    Related Links: